These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 10185343)
1. Reduce the medical, economic impact of preterm delivery. Health Care Cost Reengineering Rep; 1998 Sep; 3(9):134-7. PubMed ID: 10185343 [TBL] [Abstract][Full Text] [Related]
2. [Economical impact of preterm delivery management based on fetal fibronectin results]. García Alonso LA; Ayala Méndez JA; Jiménez Solís G; Aguilar Gutiérrez F; Díaz Cueto L Ginecol Obstet Mex; 2004 Aug; 72():385-93. PubMed ID: 15526554 [TBL] [Abstract][Full Text] [Related]
3. Detection of interleukin 6 mRNA by RT-PCR in vaginal secretions: association with preterm delivery and neonatal infection in women with preterm labour and intact membranes. Goffinet F; Kayem G; Maillard F; Trébéden H; Cabrol D; Weill B; Batteux F Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123(2):167-73. PubMed ID: 15893869 [TBL] [Abstract][Full Text] [Related]
4. Performance of cervicovaginal fetal fibronectin in a community hospital setting. Incerti M; Ghidini A; Korker V; Pezzullo JC Arch Gynecol Obstet; 2007 May; 275(5):347-51. PubMed ID: 17051404 [TBL] [Abstract][Full Text] [Related]
5. The impact of fetal fibronectin testing for women with symptoms of preterm labour in routine clinical practice within a New Zealand population. Groom KM; Liu E; Allenby K Aust N Z J Obstet Gynaecol; 2006 Oct; 46(5):440-5. PubMed ID: 16953860 [TBL] [Abstract][Full Text] [Related]
6. Negative fetal fibronectin: who is still treating for threatened preterm labor and does it help? Peláez LM; Fox NS; Chasen ST J Perinat Med; 2008; 36(3):202-5. PubMed ID: 18576928 [TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of a screen-and-treat program for asymptomatic vaginal infections in pregnancy: towards a significant reduction in the costs of prematurity. Kiss H; Pichler E; Petricevic L; Husslein P Eur J Obstet Gynecol Reprod Biol; 2006 Aug; 127(2):198-203. PubMed ID: 16303228 [TBL] [Abstract][Full Text] [Related]
8. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study. Shennan A; Crawshaw S; Briley A; Hawken J; Seed P; Jones G; Poston L BJOG; 2006 Jan; 113(1):65-74. PubMed ID: 16398774 [TBL] [Abstract][Full Text] [Related]
10. Interleukin-8 and glucose in amniotic fluid, fetal fibronectin in vaginal secretions and preterm labor index based on clinical variables are optimal predictive markers for preterm delivery in patients with intact membranes. Yoneda S; Sakai M; Sasaki Y; Shiozaki A; Hidaka T; Saito S J Obstet Gynaecol Res; 2007 Feb; 33(1):38-44. PubMed ID: 17212664 [TBL] [Abstract][Full Text] [Related]
11. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis. Odibo AO; Stamilio DM; Macones GA; Polsky D Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206 [TBL] [Abstract][Full Text] [Related]
12. Does hospitalization prevent preterm delivery in the patient with a short cervix? Fox NS; Jean-Pierre C; Predanic M; Chasen ST Am J Perinatol; 2007 Jan; 24(1):49-53. PubMed ID: 17195150 [TBL] [Abstract][Full Text] [Related]
13. [Fetal fibronectin as predictor of preterm birth]. Roubille M; Mailliavin A; Biguet-Vernier B; Bon C; Golfier F; Pichot JC Ann Biol Clin (Paris); 1999; 57(1):93-7. PubMed ID: 9920973 [No Abstract] [Full Text] [Related]
14. Hospitalization for women with arrested preterm labor: a randomized trial. Yost NP; Bloom SL; McIntire DD; Leveno KJ Obstet Gynecol; 2005 Jul; 106(1):14-8. PubMed ID: 15994611 [TBL] [Abstract][Full Text] [Related]
15. Does fetal fibronectin use in the diagnosis of preterm labor affect physician behavior and health care costs? A randomized trial. Grobman WA; Welshman EE; Calhoun EA Am J Obstet Gynecol; 2004 Jul; 191(1):235-40. PubMed ID: 15295372 [TBL] [Abstract][Full Text] [Related]
16. The value of the insulin-like growth factor binding protein-1 in the cervical-vaginal secretion detected by immunochromatographic dipstick test in the prediction of delivery in women with clinically unconfirmed preterm premature rupture of membranes. Akercan F; Cirpan T; Kazandi M; Terek MC; Mgoyi L; Ozkinay E Eur J Obstet Gynecol Reprod Biol; 2005 Aug; 121(2):159-63. PubMed ID: 16054956 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness of fetal fibronectin testing compared with digital cervical assessment of women with preterm contractions. Mateus J; Pereira L; Baxter J; Berghella V; Tolosa J Am J Perinatol; 2007 Jun; 24(6):381-5. PubMed ID: 17566945 [TBL] [Abstract][Full Text] [Related]
18. A randomized multicenter study to determine the efficacy of activity restriction for preterm labor management in patients testing negative for fetal fibronectin. Elliott JP; Miller HS; Coleman S; Rhea D; Abril D; Hallbauer K; Istwan NB; Stanziano GJ J Perinatol; 2005 Oct; 25(10):626-30. PubMed ID: 16107874 [TBL] [Abstract][Full Text] [Related]
19. Implementation of foetal fibronectin testing: Admissions, maternal interventions and costs at 1 year. Parisaei M; Currie J; O'Gorman N; Morris S; David AL J Obstet Gynaecol; 2016 Oct; 36(7):888-892. PubMed ID: 27147420 [TBL] [Abstract][Full Text] [Related]
20. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study. McParland PC; Kenyon S; Bell SC; Taylor DJ BJOG; 2006 Aug; 113(8):976; author reply 976-7. PubMed ID: 16907946 [No Abstract] [Full Text] [Related] [Next] [New Search]